CMPK2

Across TCGA pan-cancer cohorts, CMPK2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CMPK2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher CMPK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CMPK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LGG, SARC, and LIHC are the cancer types where CMPK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.185	0.738	.003	12	view →
SARC	DFS	Median	All	0.069	0.632	<.001	9	view →
LIHC	DFS	Median	All	0.151	0.555	.027	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.030	6	view →
SKCM	DFS	Median	III,IV	0.046	0.648	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CMPK2–LGG (DFS)

Open the LGG breakdown →